ALCAR.PA Carmat SA EURONEXT 13 Feb 2026: €0.10 before 18 Feb earnings, watch cash runway

ALCAR.PA stock trades at €0.10 on EURONEXT on 13 Feb 2026 as investors prepare for an earnings update on 18 Feb 2026. Volume is 807,348 today versus average volume 797,166, showing active interest. The company reports a trailing EPS of -1.15 and a market cap near €6,361,146. This earnings spotlight focuses on cash runway, clinical milestones, and valuation ahead of the report.

ALCAR.PA stock: earnings timeline and what to expect

Carmat SA (ALCAR.PA) will publish results linked to the company update on 18 Feb 2026. Management commentary will likely focus on device implant pacing, regulatory steps, and clinical enrollment. The consensus on operational metrics is thin, so the earnings call can move the stock on execution comments alone.

Investors should watch for revenue pacing and updated cash guidance. Recent EPS is -1.15, and the company carries a negative net income per share. Clinical readouts or confirmation of funding will be the main catalysts for any large price moves.

Financials and valuation: cash, ratios and Meyka grade

ALCAR.PA stock shows structural losses and a thin market cap. Trailing price averages are 50-day €0.15 and 200-day €0.59. Price to sales is 0.91 and EPS is negative, producing a negative PE. Cash per share is €0.21 and working capital is €13,280,000, indicating limited liquidity relative to burn.

Meyka AI rates ALCAR.PA with a score out of 100: 72.76 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade highlights growth potential from device approvals, but flags execution and funding risk.

ALCAR.PA earnings: catalysts and key risks

Near-term catalysts include the 18 Feb update, any clinical milestone confirmation, and partner or grant announcements. Positive trial progress could re-rate this medical device stock because the product addresses end-stage biventricular failure.

Key risks include continued losses, long inventory cycles, and a thin balance sheet. Days of inventory on hand exceed 1,033 days, a structural efficiency concern. Interest coverage is negative and enterprise value exceeds market cap, highlighting leverage and valuation complexity.

Technicals, liquidity and trading setup

Intraday range is €0.10 low to €0.11 high. Shares outstanding are 64,254,002 and daily volume near 807,348 matches the average. The 3‑month price change is down roughly 67.70%, while YTD is down 91.16%, showing steep recent selling pressure.

Short-term traders should note the wide gap to the 200-day average of €0.59 and low absolute price. Bid-ask spreads and slippage can be material at this price level. Use limit orders and watch EURONEXT liquidity before entering positions.

ALCAR.PA forecast and practical price targets

Meyka AI’s forecast model projects a base-case 12‑month price of €0.30. Compared with the current price €0.099, that implies upside of 203.03%. Meyka AI also models a conservative downside scenario at €0.03 and a bull scenario at €0.60.

Forecasts are model-based projections and not guarantees. Drivers for the base case include successful trial progress and short-term funding. A missed milestone or funding gap would push the stock toward the conservative scenario.

Final Thoughts

Key takeaways for Carmat SA (ALCAR.PA) ahead of the 18 Feb 2026 earnings update: the stock trades at €0.099 on EURONEXT with active volume of 807,348, and the fundamentals show negative EPS and tight liquidity. Meyka AI’s forecast model projects a base-case 12‑month target of €0.30, implying an upside of 203.03% versus €0.099 today. Our proprietary grade reads 72.76 (B+, BUY), reflecting clinical upside but material funding and execution risk. For traders, the earnings update will act as a binary catalyst. For longer-term investors, monitor cash runway, clinical enrollment rates, and any partner financing. Forecasts are model-based projections and not guarantees. Use position sizing and active risk controls given the stock’s volatility and low absolute price.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.